What does EyePoint, Inc. do?
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational…
What is EyePoint, Inc.'s P/E and P/B ratio?
EyePoint, Inc. has a P/E ratio of -0.1 and a P/B ratio of 0.22.
What is EyePoint, Inc.'s debt-to-equity ratio?
EyePoint, Inc. has a debt-to-equity ratio of 0.13.
How much does EyePoint, Inc. owe compared with what it owns?
EyePoint, Inc. owes $0.27 for every $1 it owns (balance sheet Jun 2026), which is low.
What is EyePoint, Inc.'s Positivity rank?
EyePoint, Inc. is ranked #803 of 6,775 companies globally and #126 of 4,000 in United States on PositoAI, with a Positivity Score of 23,787.
Does EyePoint, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for EyePoint, Inc..
Where can I read the latest news about EyePoint, Inc.?
Recent headlines about EyePoint, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does EyePoint, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of EyePoint, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.